Sotabase

Career

· Robotics Research Associate, Stanford Artificial Intelligence Laboratory (SAIL)2025–
· Researcher, Interactive Perception and Robot Learning Lab2024–
· Undergraduate Student in Computer Science, Stanford University2024–
· Geballe Dissertation Fellow, Stanford University2002–2003
· Research/Affiliation, Stanford Artificial Intelligence Laboratory (SAIL)
· Ph.D., English and American Literature, Stanford University

Publications (20)

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Proceedings of the National Academy of Sciences of the United States of America · 2009
405
cited
The ion channel TRPV1 regulates the activation and proinflammatory properties of CD4+ T cells
Nature Immunology · 2014
232
cited
The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1
Gut · 2016
117
cited
TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors
Molecular Cancer Therapeutics · 2020
35
cited
Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
Clinical Cancer Research · 2020
33
cited
Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma
Blood · 2018
16
cited
The TRPA 1 ion channel is expressed in CD 4 + T cells and restrains T-cell-mediated colitis through inhibition of TRPV 1
2017
16
cited
HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Molecular Cancer Therapeutics · 2024
14
cited
An Inhibitory Antibody against Dipeptidyl Peptidase IV Improves Glucose Tolerance in Vivo
Journal of Biological Chemistry · 2012
11
cited
Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
Therapeutic Agents: Biological · 2019
9
cited
Abstract 1781: HPN536, a T cell-engaging, mesothelin/CD3-specific TriTAC for the treatment of solid tumors
Immunology · 2018
7
cited
867 TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation
Journal for ImmunoTherapy of Cancer · 2021
6
cited
Abstract 1773: HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer
Immunology · 2018
6
cited
Abstract 933: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets
Experimental and Molecular Therapeutics · 2021
6
cited
Abstract 2928: TROP2 ProTriTAC™, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors
Cancer Research · 2023
4
cited
Abstract 3814: TriTACs are novel T cell-engaging therapeutic proteins optimized for the treatment of solid tumors and for long serum half-life
Immunology · 2018
3
cited
632 HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors
2020
1
cited
Abstract 2861: TriTAC-XR: An extended-release T cell engager platform designed to minimize cytokine release syndrome
Cancer Research · 2022
1
cited
Abstract 2927: ITGB6 ProTriTAC™, a protease-activated T cell engager prodrug targeting Integrin-β6 for the treatment of solid tumors
Cancer Research · 2023
1
cited
Abstract 913: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia
Experimental and Molecular Therapeutics · 2021
Sotabase
Timothy Yu | Researcher Profile | Sotabase | Sotabase